Detection of somatic mutations in the mitochondrial DNA control region D-loop in brain tumors: The first report in Malaysian patients.

Although the role of nuclear-encoded gene alterations has been well documented in brain tumor development, the involvement of the mitochondrial genome in brain tumorigenesis has not yet been fully elucidated and remains controversial. The present study aimed to identify mutations in the mitochondrial DNA (mtDNA) control region D-loop in patients with brain tumors in Malaysia. A mutation analysis was performed in which DNA was extracted from paired tumor tissue and blood samples obtained from 49 patients with brain tumors. The D-loop region DNA was amplified using the PCR technique, and genetic data from DNA sequencing analyses were compared with the published revised Cambridge sequence to identify somatic mutations. Among the 49 brain tumor tissue samples evaluated, 25 cases (51%) had somatic mutations of the mtDNA D-loop, with a total of 48 mutations. Novel mutations that had not previously been identified in the D-loop region (176 A-deletion, 476 C>A, 566 C>A and 16405 A-deletion) were also classified. No significant associations between the D-loop mutation status and the clinicopathological parameters were observed. To the best of our knowledge, the current study presents the first evidence of alterations in the mtDNA D-loop regions in the brain tumors of Malaysian patients. These results may provide an overview and data regarding the incidence of mitochondrial genome alterations in Malaysian patients with brain tumors. In addition to nuclear genome aberrations, these specific mitochondrial genome alterations may also be considered as potential cancer biomarkers for the diagnosis and staging of brain cancers.

Introduction

Brain and central nervous system (CNS) tumors are the second most common type of cancer in children, comprising ~21% of cases, and the third most common cancer type in adolescents, contributing to ~10% of cases (1). It is estimated that >23,800 (13,450 males and 10,350 females) new cases of brain and CNS tumors will be diagnosed and 16,700 (9,620 men and 7,080 women) brain and CNS tumor-associated mortalities will occur in the United States in 2017 (http://www.cancer.org) (2,3). The incidence of brain tumors in Malaysia was relatively low, accounting for ~1.95% of all cancer cases prior to 2003 (4). Since then, the incidence rate has been increasing rapidly, and brain and CNS tumors have become the third most common type of pediatric cancer in Malaysia, behind leukemia and lymphoma (5,6). In 2012, the incidence rate was 4.6/100,000 individuals/year (6).

The overall prognosis for brain tumors is based on tumor pathology or grade (7,8). The majority of patients who are diagnosed with malignant primary brain tumors have a poor prognosis (7,8). Therefore, it is crucial to identify novel potential bio-tumor markers for brain tumors in order to improve the diagnosis, prognosis and treatment of the disease.

Mitochondria have long been considered as crucial organelles, since they contain their own DNA (9). Prior research shows that mitochondria have a variety of roles in energy metabolism and cellular homeostasis, including ATP production, reactive oxygen species (ROS) production, metabolic homeostasis and apoptosis (10,11). Human mitochondrial DNA (mtDNA) is a closed circular, double-stranded molecule of ~16.5 kb (12). It contains genes coding for 13 polypeptide components of respiratory chain enzyme complexes (complex I, III, IV and V), two ribosomal RNAs (rRNAs) and 22 transfer RNAs (tRNAs), which are components of the mitochondrial protein translation system (12,13). mtDNA is also composed of a non-coding region known as the displacement-loop (D-loop), located between nucleotides 16,024 and 576, which contain essential elements that are responsible for the transcription and replication of the mitochondrial genome (14). Furthermore, mtDNA is considered to have a much higher mutation rate than nuclear DNA and is more sensitive to oxidative damage (15). As mtDNA is in close proximity to the respiratory chain, it is constantly exposed to endogenous ROS produced by the mitochondria that can damage DNA (16).

The first report of mtDNA mutations was described in 1998 by Polyak et al (17) in human colorectal cancer. Since then, numerous studies have been reported with >200 mtDNA mutation and/or alteration cases in cancer published worldwide (18,19). Somatic mutations of mtDNA have been identified in multiple cancer types, including breast cancer, colorectal cancer, hepatocellular carcinoma, gastric cancer and lung cancer (19–24). Therefore, mtDNA is considered to serve an important role in tumor progression and carcinogenesis. The mtDNA D-loop has been identified as a hot spot of genetic alterations in human cancer (25–27). Accumulation of mtDNA D-loop alterations may contribute to altered replication and/or transcription of mitochondrial genes, which may lead to mitochondrial dysfunction and excessive cellular ROS production.

Although there have been several alterations in mtDNA reported in patients with brain tumors (28–30), the contribution of mtDNA mutations to brain tumorigenesis remains unclear and requires additional exploration. As data on mtDNA alterations was not available for Malaysian patients with brain tumors, the D-loop mtDNA alterations were examined in patients with brain tumors of diverse types and grades. The aims of the present study were to identify mtDNA D-loop alterations, and to assess their association with clinicopathological features of brain tumors.

Materials and methods

Tumor specimens

Paired samples of brain tumor tissue and blood samples from 49 patients were collected during elective neurosurgical procedures at the Department of Neurosciences, Hospital Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia between July 2010 and December 2014. Peripheral blood specimens were obtained from the same patients as a the control. The study population consisted of 29 males (59.2%) and 20 females (40.8%) with age of patients ranging between 2 and 74 years (mean, 44.2 years). The histopathological diagnosis of the brain tumor samples was determined according to the World Health Organization (WHO) criteria (31) by a consultant neuropathologist. These neoplasms comprised 6 pilocytic astrocytoma WHO grade I (PA), 2 astrocytoma WHO grade II (A II), 5 anaplastic astrocytoma WHO grade III (AA III), 16 glioblastoma multiforme WHO grade IV (GBM IV), 3 oligodendroglioma WHO grade II (ODG), 2 ependymoma WHO grade II (EP) and 15 meningioma WHO grade I. The protocol was approved by the Research Ethics Committee of Universiti Sains Malaysia, and all patients provided written informed consent for participation. The tumor tissue biopsies and peripheral blood specimens (5 ml), obtained from all patients, were snap-frozen in liquid nitrogen and stored at −80°C until DNA extraction.

DNA extraction

Genomic DNA was extracted from brain tumor tissues and blood samples of patients using the QIAamp DNA mini kit (Qiagen GmbH, Hilden, Germany), according to the manufacturer's protocol. The concentration and quality of extracted DNA was measured using a NanoDrop ND1000 spectrophotometer (NanoDrop; Thermo Fisher Scientific, Inc., Pittsburgh, PA, USA) and 1% agarose gel electrophoresis stained with 10 mg/ml ethidium bromide (Invitrogen; Thermo Fisher Scientific, Inc.).

Polymerase chain reaction (PCR) amplification of the mtDNA D-loop

Three sets of primers were designed to amplify or target three independent but overlapping fragments that span the whole D-loop region, as listed in Table I. Briefly, PCR was performed on the SureCycler 8800 Thermal Cycler (Agilent Technologies, Inc., Santa Clara, CA, USA), in a 50 µl reaction mixture containing 100 ng DNA template, 200 µM each dNTP, 20 pMol each primer, 10 µl 5X Phusion HF buffer (Thermo Fisher Scientific, Inc.) and 2 U Phusion high-fidelity DNA polymerase (Thermo Fisher Scientific, Inc.).

Table I.

Polymerase chain reaction primers and the expected sizes of amplicons.

Primer	Forward primer, 5′-3′	Reverse primer, 5′-3′	Band size, bp
Mito-D-loop 1	5′-CCTATGTCGCAGTATCTGTC-3′	5′-TGCTTTGAGGAGGTAAGCTA-3′	491 bp (np. 113-603)[a]
Mito-D-loop 2	5′-GTCTTGTAAACCGGAGATGA-3′	5′-GAGCGAGGAGAGTAGCAC-3′	539 bp (np. 15,915–16,453)[a]
Mito-D-loop 3	5′-TACAGTCAAATCCCTTCTCG-3′	5′-AATAGGATGAGGCAGGAATC-3′	383 bp (np. 16,342–155)[a]

Nucleotide position according to the revised Cambridge Reference Sequence (NC_012920).

The cycling profile was set at 98°C initial denaturation for 1 min, followed by 35 cycles of denaturation at 98°C for 20 sec, annealing at 56°C for 20 sec, extension at 72°C for 20 sec and a final extension at 72°C for 5 min. The amplified PCR fragments were analyzed via 2% agarose gel electrophoresis using a GeneRuler 100 bp DNA ladder (Thermo Fisher Scientific, Inc.) in order to determine the expected size of the amplified PCR fragments. The PCR products with the expected size were purified with the QIAquick PCR Purification kit (Qiagen GmbH) according to the manufacturer's protocol and stored at −20°C until use for DNA sequencing analysis.

Direct sequencing of the mtDNA D-loop

Purified PCR products were sequenced in both directions using the same primers as described for the PCR reactions (Table I). Sequencing was performed using a Big Dye Terminator cycle sequencing kit (Applied Biosystems; Thermo Fisher Scientific, Inc.) according to the manufacturer's instructions, on an ABI Prism 3700 DNA Analyzer automated sequencer (Applied Biosystems; Thermo Fisher Scientific, Inc.). DNA sequencing and electropherogram results were analyzed manually and aligned using BLAST software from the NCBI site (http://www.ncbi.nlm.nih.gov/blast), and then compared with the published revised Cambridge Reference Sequence (rCRS) of the human mtDNA (NC_012920) in the MITOMAP database (http://www.mitomap.org).

Statistical analysis

The data were analyzed using GraphPad Prism software version 5 (GraphPad Software, Inc., La Jolla, CA, USA) with Fisher's exact test to calculate the significance of associations between mtDNA D-loop mutations and the clinicopathological parameters of brain tumor samples. P<0.05 was considered to indicate a statistically significant difference.

Results

Patient characteristics

Brain tumor tissue specimens from 49 Malaysian patients were obtained at the same time as blood samples, which were used as controls. If the mtDNA sequence in the tumor differed from the corresponding blood sample, this was described as a somatic mutation. The mean age of the patients at the time of initial surgery was 44.2 years (range, 2–74 years). Of these, 29 were males (59.2%) and 20 were females (40.8%). In this retrospective cohort, GBM IV represents 32.7% (n=16) of all primary brain tumors, followed by meningioma (n=15, 30.6%), PA I (n=6, 12.2%), AA III (n=5, 10.2%), ODG (n=3, 6.1%), A II (n=2, 4.1%) and EP (n=2, 4.1%).

Somatic mtDNA D-loop mutations status in brain tumors

A total of three overlapping fragments that spanned the whole 1,122 bp D-loop region were amplified in 49 brain tumor tissue samples and corresponding blood samples. The successful amplification of three fragments resulted in the amplified fragments of sizes 383, 491 and 539 bp (Fig. 1) (the total size of amplified fragments was 1,413 bp, 79% more than the entire D-loop due to the overlapping regions). Amplified fragments/products were then sequenced, and the sequenced data obtained were compared with the rCRS in the MITOMAP database.

Figure 1.

Polymerase chain reaction amplification of three overlapping fragments of mtDNA D-loop region using the designed primers. (A) Fragment size of 383 bp; (B) fragment size of 491 bp; (C) fragment size of 539 bp. Lane 1–5, tumor tissues. -ve, negative control (H2O); M, molecular weight marker (100 bp); mt, mitochondrial.

By analyzing the sequencing data, it was observed that 51% (25/49) of the patients carried a total of 48 somatic mutations at 27 positions in the D-loop of mtDNA (Table II). Among these mutations, four (176 A-deletion, 476C>A, 566C>A and 16405 A-deletion) had not previously been recorded in the MITOMAP database (Fig. 2). Therefore, it was assumed that they are novel mutations. Mutations in nucleotide 195T>C, 146T>C, 152 T>C, 204 T>C, 303 CC-insertion, 311 C-insertion and 16519T>C were also found, which have previously been reported in brain tumors (28,29,32). In addition, 94% (45/48) of these mutations were homoplasmic and 19% (9/48) of them were located in the D310 mononucleotide repeat (np 303–315). Representative DNA sequence chromatograms are presented in Fig. 2.

Table II.

Mitochondrial DNA D-loop somatic mutations in patients with brain tumors.

Patient code	Tumor type	Nucleotide position	Somatic mutation	Homoplasmy/heteroplasmy	Novel/reported	(Refs.)
ID003	GBM IV	16265	A-G	Homoplasmy	Bladder	(33)
					Leukemia	(34)
					Prostate cancer	(35)
ID004	GBM IV	303	CC insertion	Homoplasmy	Brain tumor	(32)
					Gastric cancer	(36)
					Breast	(37)
					Oral	(38
		414	T-G	Homoplasmy	Colorectal	(39)
		476[a]	C-A/C	Heteroplasmy	Novel[a]	Present study
ID005	GBM IV	195	T-C	Homoplasmy	Brain tumor	(28,29)
					Ovarian	(40)
					Breast	(41)
					Leukemia	(42)
ID006	AA III	16356	T-C	Homoplasmy	Brain tumor	(28)
					Breast	(41)
ID007	Meningioma I	249	A deletion	Homoplasmy	Nasopharyngeal	(43)
					carcinoma	(44)
					Breast	(35[a])
					Prostate cancer
		73	A-G	Homoplasmy	Prostate cancer	(45)
					Brain tumor	(29)
					Breast	(41)
					Leukemia	(42)
ID008	GBM IV	249	A deletion	Homoplasmy	Nasopharyngeal	(43)
					carcinoma	(44)
					Breast	(35[a])
					Prostate
		311	C insertion	Homoplasmy	Brain tumor	(32)
					Breast	(37)
					Leukemia	(42)
		73	A-G	Homoplasmy	Prostate cancer	(45)
					Brain tumor	(29)
					Breast	(41)
					Leukemia	(42)
		16356	T-C	Homoplasmy	Brain tumor	(28)
					Breast	(41)
ID011	PA	303	C insertion	Homoplasmy	Brain tumor	(32)
					Gastric cancer	(36)
					Breast	(37)
					Oral	(38)
		311	C insertion	Homoplasmy	Brain tumor	(32)
					Breast	(37)
					Leukemia	(42)
ID013	PA	16325	T-C	Homoplasmy	Brain tumor	(32)
					Leukemia	(34)
					Breast	(37)
ID014	AA III	249	A deletion	Homoplasmy	Nasopharyngeal	(43)
					carcinoma	(44)
					Breast	(35[a])
					Prostate
		311	C insertion	Homoplasmy	Brain tumor	(32)
					Breast	(37)
					Leukemia	(42)
ID017	GBM IV	311	C insertion	Homoplasmy	Brain tumor	(32)
					Breast	(37)
					Leukemia	(42)
		511	C-T	Homoplasmy	Cervical cancer	(46)
ID019	Meningioma I	146	T-C	Homoplasmy	Brain tumor	(29)
					Breast	(37)
					Leukemia	(42)
					Oral	(38)
		204	T-C	Homoplasmy	Brain tumor	(28)
					Ovarian	(47)
					Leukemia	(34,42)
		16519	T-C	Homoplasmy	Brain tumor	(28)
					Leukemia	(34)
					Gastric cancer	(36)
					Breast	(41)
ID020	GBM IV	195	T-C	Homoplasmy	Brain tumor	(28,29)
					Ovarian	(40)
					Breast	(41)
					Leukemia	(42)
		303	CC insertion	Homoplasmy	Brain tumor	(32)
					Gastric cancer	(36)
					Breast	(37)
					Oral	(38)
		411	C-G/C	Heteroplasmy	Leukemia	(34)
		16381	T-C	Homoplasmy	Reported in MITOMAP	MITOMAP
ID021	Meningioma I	176[a]	A deletion	Homoplasmy	Novel[a]	Present study
		16265	A-G	Homoplasmy	Bladder	(33)
					Leukemia	(34)
					Prostate cancer	(35)
ID022	Meningioma I	411	C-G	Homoplasmy	Leukemia	(34)
		432	A-C	Homoplasmy	Reported in MITOMAP	MITOMAP
ID024	GBM IV	186	C-G	Homoplasmy	Oral cancer	(48)
ID026	GBM IV	71	G deletion	Homoplasmy	Oral cancer	(49)
		311	C insertion	Homoplasmy	Brain tumor	(32)
					Breast	(37)
					Leukemia	(42)
ID027	GBM IV	61	C-A	Homoplasmy	Reported in MITOMAP	MITOMAP
		16381	T-C	Homoplasmy	Reported in MITOMAP	MITOMAP
		16405[a]	A deletion	Homoplasmy	Novel[a]	Present study
ID030	GBM IV	311	C insertion	Homoplasmy	Brain tumor	(32)
					Breast	(37)
					Leukemia	(42)
		523–524	AC deletion	Homoplasmy	Reported in MITOMAP	MITOMAP
ID036	Meningioma I	503	A-G	Homoplasmy	Reported in MITOMAP	MITOMAP
		566[a]	C-A	Homoplasmy	Novel[a]	Present study
ID038	Meningioma I	146	T-C	Homoplasmy	Brain tumor	(29)
					Breast	(37)
					Leukemia	(42)
					Oral	(38)
		152	T-C/T	Heteroplasmy	Brain tumor	(29)
					Breast	(20,41)
					Laryngeal carcinoma	(50)
ID039	Meningioma I	472	A-G	Homoplasmy	Reported in MITOMAP	MITOMAP
ID042	GBM IV	16519	T-C	Homoplasmy	Brain tumor	(28)
					Leukemia	(34)
					Gastric cancer	(36)
					Breast	(41)
ID044	GBM IV	146	T-C	Homoplasmy	Brain tumor	(29)
					Breast	(37)
					Leukemia	(42)
					Oral	(38)
		204	T-C	Homoplasmy	Brain tumor	(28)
					Ovarian	(47)
					Leukemia	(34,42)
ID045	Meningioma I	176[a]	A deletion	Homoplasmy	Novel[a]	Present study
ID047	Ependymoma	16519	T-C	Homoplasmy	Brain tumor	(28)
					Leukemia	(34)
					Gastric cancer	(36)
					Breast	(41)

Novel mutations; areported as a polymorphism; PA, pilocytic astrocytoma; AA III, anaplastic astrocytoma III; GBM, glioblastomas multiform.

Figure 2.

Representative sequencing results depicting examples of mtDNA D-loop mutations in brain tumor tissue samples. (A) Chromatograms demonstrate a mutation of T to C transition at nucleotide position 195. (B) Novel heteroplasmic mutation of C to A transversion at nucleotide 476. In the tumor sample, there are two peaks that represent a mixture of C and A nucleotides. Mt, mitochondrial.

mtDNA D-loop polymorphism status in brain tumors

Any DNA sequence variation present in the peripheral blood and tumor tissue of patients was classified as a polymorphism. In the present study, 210 polymorphisms were identified at 26 nucleotide positions (Table III). The majority of polymorphisms identified in the present study were found in the nucleotides 263A>G, 16189T>C, 16261C>T and 16271T>C.

Table III.

Mitochondrial DNA D-loop polymorphisms in patients with brain tumors.

Nucleotide position	Base variation	Cases, n
143	G→A	2
189	A→G	1
199	T→C	3
263	A→G	20
318	T→C	3
16093	T→C	10
16129	G→A	13
16162	A→G	11
16172	T→C	4
16189	T→C	23
16223	C→T	12
16256	C→T	10
16259	T→C	5
16261	C→T	24
16271	T→C	19
16278	C→T	5
16288	T→C	8
16290	C→T	2
16298	T→C	2
16304	T→C	9
16309	A→G	5
16311	T→C	3
16319	G→A	6
16325	T→C	2
16362	T→C	3
16390	G→A	5

Associations between D-loop mutation status and clinicopathological parameters of brain tumors

Table IV describes the D-loop mutation status and its association with patient gender, age, race and histological tumor type. No significant association was observed between the D-loop mutation status and gender (P=1.0); however, the number of patients with D-loop mutations tends to be higher in males (n=15/25, 60%) than females (n=10/25, 40%).

Table IV.

Clinicopathological characteristics of patients with brain tumors and D-Loop mutation status.

	D-loop status, n (%)
Parameter	Total patients, no. (%)	Mutation	No mutation	P-value
No. of patients	49 (100)	25 (51.0)	24 (49.0)
Sex
Male	29 (59.2)	15 (51.7)	14 (48.3)	1.000
Female	20 (40.8)	10 (50.0)	10 (50.0)
Age, years
<45	20 (40.8)	7 (35.0)	13 (65.0)	0.0845
≥45	29 (59.2)	18 (62.1)	11 (37.9)
Ethnicity
Malaysian	42 (85.7)	22 (52.4)	20 (47.6)	0.8716
Chinese	5 (10.2)	2 (40.0)	3 (60.0)
Indian	2 (4.1)	1 (50.0)	1 (50.0)
Histological tumor types (grade)
Pilocytic astrocytoma (I)	6 (12.2)	2 (33.3)	4 (66.7)	0.1282
Astrocytomas (II)	2 (4.1)	0 (0)	2 (100)
Anaplastic astrocytomas (III)	5 (10.2)	2 (40.0)	3 (60.0)
Glioblastomas multiform (IV)	16 (32.7)	12 (75.0)	4 (25.0)
Ependymoma	2 (4.1)	1 (50.0)	1 (50.0)
Oligodendroglioma	3 (6.1)	0 (0)	3 (100)
Meningioma (I)	15 (30.6)	8 (53.3)	7 (46.7)

In the <45 and ≥45 year groups, the association was determined to be non-significant, although D-loop mutations were observed to be more evident in the ≥45 year group (n=18/25, 72%) compared with in the <45 year group (n=7/25, 28%). In addition, mutations of the D-loop had no significant association with the ethnicity of patients.

As presented in Table IV, the D-loop mutations were frequent in GBM IV (n=12/25, 48%), followed by distribution in meningioma (n=8/25, 32%), and equal in PA I and AA III (n=2/25, 8%). Furthermore, no significant association between D-loop mutations and any of these histological tumor types was observed.

Discussion

DNA mutation in mitochondria is one of the most common genetic alterations in cancer (51,52) and has been widely investigated (51–53). mtDNA alterations were reported to be frequently activated via certain nucleotide changes in the control region that is known as the D-loop region (17,18,54). This area has been identified as a hot spot region for somatic mtDNA mutations in various types of human cancer, including breast, colorectal and lung cancer (55–58). Thus far, the majority of research on tumor-driving mutations and associated mutations in mtDNA has focused on alterations of the D-loop in the mitochondrial genome (26,28,38). Lin et al (38) detected somatic D-loop mutations in 62.5% patients with oral squamous cell carcinoma. Rahmani et al (41) reported the presence of mtDNA D-loop mutations in 52% patients with breast cancer. In cases of brain tumors, Montanini et al (59) identified sequence alterations in 36% of patients with malignant gliomas, primarily in the D-loop region.

Until now, there were no published studies or data available on mtDNA mutations in the brain tumors of Malaysian patients. As the majority of the available studies on mtDNA mutations in brain tumors were conducted on cohorts in Western countries, it was assumed that this is the first study involving Malaysian patients. In the current study, the frequency of mtDNA mutations was identified in 51% of the patients tested, which was high when compared with three prior studies of German patients with brain tumors: 41% glioblastoma (28), 43% neurofibromatosis type I (60) and 40% medulloblastoma (61). However, this rate was lower than that reported for pilocytic astrocytoma (84%) by Lueth et al (32). The difference in the frequency of mtDNA mutations may be due to sample size, or the genetic differences among the studied populations.

The majority of nucleotide changes reported in the present study have been previously described; mutations at nucleotide positions 303, 311, 146, 152, 204, 16,356 and 16,519 have been reported in patients with brain tumors (28,29,32). All of these reported mutations were also observed in our brain tumor samples. In addition, changes in these nucleotides were observed in several types of cancer, including breast cancer, leukemia, gastric cancer and oral cancer (Table II).

The mtDNA D-loop contains three hypervariable segments: HVI (16024–16383), HVII (57–372) and HVIII (438–574), which are highly polymorphic (18,62,63). In the present study, the most frequent D-loop mutation was in the HVII segment, particularly in a polycytosine (poly-C) mononucleotide repeat tract located between nucleotides 303 and 315, termed D310 (55,64,65). The present findings confirm the previous observation that base deletions or insertions in D310, are the most common mutations of mtDNA in human cancer, including brain cancer (55,59,65). The D-loop was reported to be more sensitive to oxidative stress than other mtDNA regions (66). Damage in poly-C sequences by extensive oxidative stress may lead to slippage and/or misincorporation during the replication or repair of mtDNA by mitochondrial DNA polymerase γ, and subsequently give rise to mtDNA mutations in cancer cells (67).

In the present study, four mutations were identified in the D-loop, including 176 A-deletion (in 2 cases), 476C>A (in 1 case), 566C>A (in 1 case) and 16,405 A-deletion (in 1 case), which have not previously been reported in MITOMAP databases, and they were considered to be novel mutations in the mtDNA D-loop.

In the present study, 210 germline nucleotide changes were identified in peripheral blood and tumor tissue samples of patient cohort. All of these changes were considered to be polymorphisms. Polymorphisms in 263A>G, 16189T>C, 16261C>T and 16271T>C were the most frequently observed in the present study. Yacoubi Loueslati et al (68) determined that Tunisian female patients who harbored a 263A>G germline polymorphism exhibited a weak protective effect against breast cancer risk. Previously, attention has been paid to the carriers of the 16189T>C polymorphism in oncological studies, due to their susceptibility to endometrial cancer progression (69–71). The 16189T>C polymorphism has been hypothesized to affect mtDNA replication and its cellular copy number (72). In addition to endometrial cancer, the 16189T>C polymorphism has been identified in pilocytic astrocytoma (32), breast cancer (26,73) and coronary artery disease (74). Thus far, no strong association between these polymorphisms and the etiology of brain tumors has been observed.

By analyzing the association between D-loop mutational status and clinicopathological characteristics, no significant difference was observed between the D-loop mutation group and the non-mutation group with regard to age, gender, race and histological tumor type. However, it was suggested that these mtDNA D-loop mutations are capable of initiating and promoting tumorigenesis in the brain.

As only a limited number of studies have analyzed the role of mtDNA mutations in brain tumors, it remains unclear whether the mtDNA mutation has prognostic value. In a prior study, Montanini et al (59) reported that mtDNA mutations have no prognostic effect in gliomas. Similarly, Vidone et al (75) suggested that mtDNA genotyping may not be an efficient molecular tool to predict prognosis. There is still controversy regarding the precise prognostic role of mtDNA alterations in brain tumors (30,59,75). Additional studies with larger populations are required to clarify the prognostic impact of the mtDNA alteration status in brain tumors.

In summary, the present study identified a high frequency of D-loop region mtDNA mutations in Malaysian patients with brain tumors. Although no significant association was observed between mtDNA mutations and clinicopathological parameters, the present study is able to provided novel data (local data as well as global data) of an association between mtDNA mutations and the pathogenesis of brain tumors. This may also provide important information as to how mtDNA defects lead to cancer. The alterations of mtDNA in tumorigenesis may be used in the future as novel potential target biomarkers for the diagnosis, prognosis and treatment of brain tumors.